VX-864: A Study Drug for People with Alpha-1 Antitrypsin Deficiency who have the PiZZ Genotype
Alpha-1 Antitrypsin (ATT) Deficiency with the PiZZ Genotype is a genetic disorder that may result in severe health issues such as lung or liver disease. VX-864 is a study drug to improve the health of people with this condition. Research is needed to learn the safety and effectiveness of VX-864. The information we gain may aid future patients.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
- Ages 18 to 80 years old
- PiZZ genotype diagnoses
- Able to attend in person at the University of Utah
- Pulmonary (lung) diseases such as lung cancer
- Unable to stop augmentation therapy (use of healthy blood from others to improve the amount of ATT in the lungs)
- Use of steroids for more than 3 months starting the study
- Significant alcohol use 3 months before starting the study
- Use of inhaled cannabis or cigarette smoking 6 months before starting the study or use of illegal drugs 1 year before starting the study
Will I be paid for my time?